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Abstract 
 
Objective. Candida esophagitis belongs to the most common AIDS-defining diseases, however, 
a comprehensive immune pathogenic concept is lacking.  
Design. We investigated the immune status of 37 HIV-1-infected patients from the Swiss HIV 
cohort study at diagnosis of Candida esophagitis, 1 year before, 1 year later and after 2 years of 
suppressed HIV RNA. We compared these patients to 3 groups: 37 HIV-1-infected patients 
without Candida esophagitis but similar CD4 counts as the patients at diagnosis (advanced HIV 
group), 15 HIV-1-infected patients with CD4 counts >500 cells/µl, CD4 nadir >350 cells/µl and 
suppressed HIV RNA under combination antiretroviral therapy (cART) (early cART group), 
and 20 healthy individuals. 
Methods. We investigated phenotype, cytokine production and proliferative capacity of 
different immune cells by flow cytometry and ELISpot. 
Results. We found that patients with Candida esophagitis had nearly abolished CD4 
proliferation in response to C. albicans, significantly increased percentages of dysfunctional 
CD4 cells, significantly decreased cytotoxic NK-cell counts and peripheral innate lymphoid 
cells and significantly reduced IFN-  and IL-17 production compared to the early cART group 
and healthy individuals. Most of these defects remained for more than 2 years despite viral 
suppression. The advanced HIV group without opportunistic infection showed partly improved 
immune recovery. 
Conclusions. Our data indicate that Candida esophagitis in HIV-1-infected patients is caused 
by an accumulation of multiple, partly Candida-specific immunological defects. Long-term 
immune recovery is impaired, illustrating that specific immunological gaps persist despite 
cART. These data also support the rationale for early cART initiation to prevent irreversible 
immune defects. 
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Introduction 
 
The risk of opportunistic infections (OI) in patients with human immunodeficiency virus (HIV) 
infection has markedly declined since 1996 because of the widespread use of combination 
antiretroviral therapy (cART) [1]. Nevertheless, OIs still remain a leading complication with an 
incidence of 16% in late presenting patients [2]. Absolute CD4 counts <200 cells/μl and 
uncontrolled HIV RNA replication are well-described major risk factors for the development of 
OI, yet they also occur in patients with CD4 counts >200 cells/μl with an incidence of 10.5 per 
1000 patient years follow-up, highlighting that apart from the absolute CD4 counts additional 
risk factors for OI must be present [3]. This is further supported by recent studies documenting 
that early initiation of cART at CD4 >500 cells/μl is beneficial as it significantly reduces the 
risk for OI and malignancies [4, 5]. However OIs are not completely eliminated. However, why 
certain HIV-infected patients are susceptible to specific OIs and how the infection influences 
long-term immune recovery has only been scarcely investigated. 
Candida esophagitis is one of the most common AIDS-defining diseases, occurring in up to 10-
15% of HIV-infected patients before introduction of cART [1, 6, 7]. Importantly, Candida 
esophagitis is often the first opportunistic infection and also develops in patients with rather 
high CD4 counts suggesting that the functionality of immune responses is diminished [7].  
Earlier studies considered that susceptibility to Candida esophagitis is enhanced by a lack of 
protective Th1 responses and/or a shift to Th2 responses [8]. However, recent studies show that 
individuals with impaired IL-17 responses exhibit enhanced susceptibility to chronic 
mucocutaneous candidiasis [9]. In the context of HIV, progressive infection is accompanied by 
continuous loss of Th17 cells [10] and a decrease in the ratio of Th17 to Th1 cells in peripheral 
blood [11]. Recently, it has been demonstrated in a mouse model of oropharyngeal candidiasis 
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that IL-17 secreting RORγt+ type 3 innate lymphoid cells (ILC) also contribute to fungal 
clearance [12]. Moreover, natural killer (NK) cells are increasingly considered as part of the 
host defense against fungi [13] and their function was shown to be impaired against 
Cryptococcus neoformans in HIV-infected patients [14].  
In this study, we took the advantage of prospectively stored patient samples within the Swiss 
HIV Cohort Study and investigated the numbers and functions of different immune cell subsets 
in patients with Candida esophagitis over a longitudinal follow-up, including samples before 
disease development and after long-term suppression of HIV RNA and compared them to 3 
groups of individuals, including HIV-infected patients with similarly advanced HIV infection 
without OI, HIV-infected patients that initiated cART at CD4 nadirs >350 cells/μl and were 
HIV RNA suppressed, and healthy individuals. 
 
Methods  
 
Patients and healthy blood donors 
 
The Swiss HIV Cohort Study (SHCS) is a large prospective observational cohort study with 
continuous enrolment of adult HIV-infected individuals initiated in 1988 and approved by the 
local institutional review boards [15]. Basic socio-demographic characteristics, data on clinical 
course, antiretroviral therapy, immunologic and virologic parameters are collected at enrolment 
and every 6 months thereafter. Viable PBMC and plasma are stored every 6-12 months. Ethical 
approval and written informed consent from all patients enrolled in the SHCS have been 
obtained. 
The diagnosis Candida esophagitis was based on clinical findings defined according to CDC 
criteria [16]. From January 2000 until December 2013, 465 HIV-1 infected patients were 
diagnosed with Candida esophagitis. Of these 277 patients had Candida esophagitis as first and 
only AIDS-defining disease. Of these 37 patients with available longitudinal peripheral blood 
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mononuclear cells (PBMC) were included. We analysed cryopreserved PBMC from three time 
points: 6-18 months before diagnosis, at diagnosis (+/-6 months) and 6-18 months after 
diagnosis. For patients with suppressed HIV RNA (<50 copies/ml) over 2 years an additional 
time point was included. These patients were compared to 3 groups. (i) HIV-1-infected patients 
with similarly advanced disease but without OI. Patients were matched to Candida esophagitis 
patients according to CD4 counts (+/-25 cells/μl), date of diagnosis of Candida esophagitis, use 
of cART, gender, age and absence of other OI within 6 months prior to sample collection [17]. 
As for the Candida esophagitis patients, four time points were analysed. (ii) 15 SHCS patients 
with well-controlled HIV-1 infection from outpatients of the HIV clinic at the University 
Hospital of Basel. Patients had the following criteria: HIV CDC A1 or A2 classification with 
suppressed HIV RNA (<50 copies/ml) and stable cART therapy for at least 6 months, CD4 
counts >500 cells/μl and CD4 nadir >350 cells/μl. (iii) 20 healthy individuals after receipt of 
informed consent according to the ethic approval from the Ethikkommission Nordwest- und 
Zentralschweiz (EKBB 242/11). For both latter groups only one time point was analysed. 
Baseline characteristics of patients and healthy individuals are included in Table 1.  
 
Generation of heat-inactivated C. albicans 
 
A mixture of C. albicans strain SC5314 yeast and hyphae was cultured and heat-inactivated as 
previously described [18, 19].  
 
Phenotypic characterization 
 
T-cell activation/exhaustion was analysed by staining with anti-CD3-PerCP, anti-CD4-
PacificBlue, anti-CD8-APC, anti-CD25-PE/Cy7 and anti-CD279-PE (PD-1); innate lymphoid 
cells (ILCs) by staining with anti-Lineage-Cocktail-APC (anti-
CD3/CD14/CD16/CD19/CD20/CD56) and anti-CD127-PE; NK-cell subsets by staining with 
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anti-CD3-PerCP, anti-CD14-FITC, anti-CD19-PE/Cy7, anti-CD56-APC/Cy7, anti-CD16-
PacificBlue (all Biolegend), anti-NKG2A-APC (clone #131411) and anti-NKG2C-PE (both 
R&D Systems) [20]. Samples were acquired on a CyAn ADP Analyzer (Beckman Coulter) and 
data analyzed with FlowJo software vX.0.7. 
 
ELISPOT assay 
 
Interferon-gamma (IFN- ) and interleukin (IL)-17 enzyme-linked immunosorbent spot 
(ELISPOT, Mabtech) were performed according to manufacturer’s instructions as previously 
published [21]. Briefly, 3-5x10
5
 cells/well were stimulated in duplicates with C. albicans (MOI 
0.05), 0.05 µg/ml Cytomegalovirus (CMV) pp65 (JPT Peptide Technologies) or 0.5 µg/ml 
staphylococcal enterotoxin B (SEB; Sigma-Aldrich) for 72 hours. The number of spot forming 
counts (SFC) per well was counted by ELISPOT reader (Cellular Technologies Ltd.). Data are 
shown after subtraction of unstimulated controls. 
 
Proliferation assay 
 
PBMC were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE, Invitrogen) 
according to manufacturer’s instructions and stimulated with C. albicans (MOI 0.05) or 0.5 
µg/ml SEB for 7 days in RPMI 1640 (Gibco) with 5% pooled human serum. Medium was 
replenished as needed. Cells were stained with anti-CD3-PerCP, anti-CD4-PacificBlue, anti-
CD8-APC and anti-CD56-APC/Cy7 (all Biolegend) and acquired on a CyAn ADP Analyzer 
(Beckman Coulter) and data analyzed with FlowJo software vX.0.7. 
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Statistical analysis 
 
Comparisons between 2 groups were performed with the 2-sided Mann-Whitney U test. P≤.05 
was considered statistically significant. Statistical analyses were done using GraphPad Prism 
6.0f and Stata 13.1 software (StataCorp LP). Shown are median values + interquartile ranges 
(Tukey plots). 
 
Results  
 
Patients with Candida esophagitis have low and dysfunctional CD4 cells and decreased 
Candida-specific cytokine responses and proliferative capacity  
 
We first analysed T-cell phenotype and function of patients diagnosed with Candida esophagitis 
and compared them to HIV-1-infected individuals with early initiation of cART and sustained 
viral suppression (<50 copies/ml) and healthy individuals (for baseline characteristics of 
patients and healthy individuals see Table 1).  
As expected from earlier studies, absolute CD4 counts were significantly lower in Candida 
esophagitis patients compared to patients with early initiated cART and healthy individuals 
(Fig. 1a) and the frequencies of exhausted PD-1
+
 and activated/regulatory CD25
+
 CD4 cells 
were significantly increased compared to healthy individuals (Fig. 1b). The median percentage 
of CD25
+
 CD4 cells was 6-fold higher in patients with Candida esophagitis compared to healthy 
individuals. In accordance with the significantly reduced number of functional CD4 cells, the 
IFN-  and IL-17 responses of PBMC to the superantigen SEB or C. albicans were significantly 
lower in Candida esophagitis patients compared to patients with early initiated cART and 
healthy individuals. The IFN-  response to CMV pp65 in CMV seropositive donors was not 
affected, showing that viral reactivation was still able to trigger functional immune responses 
independent of the CD4 cell count (Fig. 1c,d).  
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In line, the proliferative capacity of CD4 and CD8 cells to C. albicans was significantly lower 
in patients with Candida esophagitis compared to healthy individuals (Fig. 1e,f). The median 
percentage of proliferating CD4 cells was 7-fold and of proliferating CD8 cells 12-fold 
decreased compared to healthy individuals. Interestingly, CD4 proliferation to SEB was 
comparable to healthy individuals. To examine whether the inability to proliferate was due to a 
lack of IL-2 production we supplemented some cultures with 50 U/ml recombinant IL-2 on day 
2. However, T-cell proliferation was not improved (Supplemental Fig. 1, 
http://links.lww.com/QAD/A920).  
Thus, development of Candida esophagitis was associated with reduced and dysfunctional CD4 
cells that showed significant impairments in cytokine production and proliferation to specific 
antigens.  
 
Patients with Candida esophagitis have decreased peripheral NK cells and innate 
lymphoid cells (ILC) 
 
NK cells and ILC are increasingly considered as part of the host defense against fungi. We 
therefore investigated whether these cells and their functionality are also impaired in patients 
with Candida esophagitis. 
Absolute NK-cell counts (CD3
-
CD56
+
) and especially the cytotoxic CD16
+
 NK-cell subset were 
significantly lower in patients with Candida esophagitis compared to patients with early 
initiated cART and healthy individuals (Fig. 2a). The absolute number of CD16
+
 NK cells was 
with a median of 42 cells/µl nearly 5-fold lower than in healthy controls (201 cells/µl). The 
percentages of NK cells expressing the inhibitory receptor NKG2A was higher in cases with 
Candida esophagitis than in the other groups, while the percentage of cells expressing the 
activating receptor NKG2C was higher in Candida esophagitis cases and in HIV-1-infected 
virologically suppressed patients than in healthy individuals (Fig. 2b). The proliferative capacity 
of NK cells to C. albicans was not significantly affected (Fig. 2c). 
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Similar to NK cells, also peripheral ILC counts (lineage
-
CD127
+
) were significantly reduced in 
patients with Candida esophagitis compared to patients with early initiated cART and healthy 
individuals (Fig. 2d). 
In conclusion, additionally to defective CD4 cell responses, patients with Candida esophagitis 
had significantly reduced numbers of NK cells and ILC. 
 
Despite higher CD4 counts at diagnosis, the proliferative responses to C. albicans and NK-
cell counts and function are impaired  
Next, we examined whether higher CD4 counts at diagnosis of Candida esophagitis are 
associated with better functionality of the different cell subsets (Fig. 3). 
Patients with CD4 counts >350 cells/µl (18 of 37 patients) showed decreased percentages of 
dysfunctional PD-1
+
 and CD25
+
 CD4
 
cells and increased cytokine responses to SEB and C. 
albicans compared to patients with CD4 counts <200 cells/µl (12 of 37 patients; Fig. 3a-c; 
supplemental Table 1). By contrast, CMV-specific responses were comparable regardless of the 
absolute CD4 counts. The proliferative response to C. albicans was reduced even in patients 
with CD4 counts >350 cells/µl (Fig. 3d).  
Although NK-cell counts and the percentage of cytotoxic CD16
+
 NK cells increased with higher 
CD4 counts, the absolute numbers of cytotoxic NK cells in patients with CD4 counts >350 
cells/µl still remained more than 4-fold reduced compared to healthy individuals (Fig. 3e). The 
number of ILC in peripheral blood also significantly increased with higher CD4 counts (Fig. 
3f).  
These data highlight, that CD4 phenotype and cytokine production and ILC counts normalized 
with increasing CD4 counts whereas the proliferative capacity of CD4 cells specifically to C. 
albicans and the number of cytotoxic NK cells were strongly impaired in all patients with 
Candida esophagitis irrespective of the CD4 count.  
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Patients with Candida esophagitis show a significant drop in CD4 counts and nearly 
abolished T-cell proliferation to C. albicans at diagnosis and retain immunological 
impairments even after disease resolution and successful cART 
 
We further analysed the immune status of patients with Candida esophagitis prior to disease 
development to identify immunological changes associated with disease development and after 
disease resolution and successful cART to identify possible long-term defects. We therefore 
additionally examined PBMC 6-18 months before diagnosis, after disease resolution (6-18 
months after diagnosis) and after successful cART with stably suppressed HIV RNA (<50 
copies/ml) for more than 2 years (Fig. 4).  
Interestingly, patients with Candida esophagitis showed a significant drop in absolute CD4 
counts at diagnosis and nearly abolished proliferation of CD4 and CD8 cells in response to 
stimulation with C. albicans. Proliferation to SEB was not significantly affected. Also NK-cell 
proliferation in response to C. albicans dropped during development of Candida esophagitis. 
In line with previous studies, Candida esophagitis patients with low CD4 nadirs (<320 cells/µl, 
median 87 cells/µl) restored CD4 counts after viral suppression to a lower level compared to 
patients with early cART and higher CD4 nadirs (>350 cells/µl, median 397 cells/µl) (Fig. 4a). 
The percentage of CD25
+
 CD4 cells and the IFN-  responses to SEB and C. albicans 
normalized after suppression of viral replication, whereas the IL-17 response remained impaired 
despite long-term viral suppression under cART (Fig. 4b-d). The proliferative capacity of CD4 
cells to C. albicans after suppression of HIV replication recovered but remained in median 
lower than in patients with early initiated cART and healthy individuals (Fig. 4e,f).  
Median NK-cell counts remained below 200 cells/µl despite viral suppression. Although the 
percentage of CD16
+
 cells increased, the absolute number of cytotoxic CD16
+
 NK cells 
remained more than 3.5-fold lower compared to healthy individuals (Fig. 4g). By contrast, the 
percentages of NKG2A
+
 and NKG2C
+
 NK cells and the proliferative responses were 
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comparable to healthy controls (Fig. 4h,i). Similarly to NK cells, also ILC counts remained 2.5-
fold reduced for at least 2 years after viral suppression (Fig. 4j). NK-cell and ILC reconstitution 
seemed to correlate directly with CD4 reconstitution (Supplemental Fig. 2, 
http://links.lww.com/QAD/A920). 
These data show that development of Candida esophagitis is associated with a drop in absolute 
CD4 counts and proliferative capacity of Candida-specific T cells and that despite successful 
cART, patients with previous Candida esophagitis have prolonged immune defects of CD4 
cells, NK cells and ILC. 
 
Patients with similarly advanced HIV infection but without an opportunistic infection 
show overall better immune recovery after successful cART 
 
The last comparator group consisted of patients with similarly advanced HIV infection but 
without OI. These patients were matched to Candida esophagitis patients according to CD4 
counts, use of cART, gender, age and absence of other OI within 6 months prior to sample 
collection. Also the viral load was comparable between these two patient groups. Notably, 
patients with similarly advanced HIV infection but without OI showed overall very similar 
immune cell impairments and reconstitution as patients with Candida esophagitis 
(Supplemental Fig. 3, http://links.lww.com/QAD/A920). However, they differed by a two-fold 
lower percentage of CD25
+
 CD4 cells prior to disease development and consistently higher CD4 
proliferation to C. albicans. Additionally, long-term recovery of the IL-17 response, total NK 
cells, CD16
+
 cytotoxic NK cells and ILCs was better in these patients without Candida 
esophagitis. 
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Discussion  
The detailed pathogenesis of OIs is still unknown for many pathogens. Candida esophagitis is 
one of the most frequent opportunistic diseases in untreated HIV-infected individuals but also 
occurs in patients with other underlying conditions.   
In this study investigating in depth 37 HIV-1-infected Candida esophagitis patients compared to 
advanced HIV-1-infected patients without OI, HIV-1-infected patients with early initiation of 
cART and healthy individuals we found that patients with Candida esophagitis showed i) a 
significant drop in CD4 counts at diagnosis, ii) a nearly abolished proliferative capacity to C. 
albicans, iii) an impaired IFN-  and IL-17 production to C. albicans and iv) a dysfunction of 
CD4 cells with increased percentages of CD25
+ 
and PD-1
+
 cells. Additionally, these patients had 
significantly decreased peripheral ILCs and cytotoxic NK-cell counts. Recovery of the 
proliferative capacity of CD4 cells and IL-17 production to C. albicans and of ILCs and 
cytotoxic NK cells was impaired for years despite effective cART.  
 
HIV infection is commonly associated with an inability to proliferate and produce IL-2. Even 
patients with normal IFN-  production often have a proliferative defect to different antigens, 
especially patients with previously low CD4 counts and persistent HIV replication [22-24]. In 
line with these data, we observed an overall decreased proliferative capacity to Candida in 
patients with Candida esophagitis at diagnosis and even after recovery of the IFN-  response. 
These findings suggest that the proliferative defect could contribute to disease development and 
that these patients might remain vulnerable despite effective cART.  
CD4 T cells from chronically infected HIV patients show diminished IFN-  and IL-17 
production [25], but data on cytokine production in response to different fungi in HIV-infected 
patients is scarce. This study demonstrates that all patients with advanced HIV infection 
including patients with and without Candida esophagitis had an overall impaired IFN-  and IL-
17 production to C. albicans, which probably is partly due to the significantly reduced CD4 
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count. However, HIV-infected patients with early initiation of cART had comparable or even 
higher Candida-specific cytokine responses compared to healthy individuals despite 
significantly reduced CD4 counts, showing that low CD4 counts do not necessarily lead to 
reduced antigen-specific responses. Similarly, CMV pp65-specific IFN-  production by CMV-
seropositive patients was comparable in all groups, independent of CD4 counts. It is however 
possible, that patients with acute Candida esophagitis have additional impairments in antigen-
presenting cells leading to reduced T-cell responses or that Candida-specific T cells in these 
patients are recruited to sites of infection and therefore disappear from the blood. Interestingly, 
the recovery of IL-17-producing cells was slower in patients with Candida esophagitis 
compared to patients with advanced HIV infection without OI. This data fortify previous 
findings in chronic mucocutaneous candidiasis in humans and oropharyngeal candidiasis in 
mice [9-11, 25, 26].  
We further found that patients with Candida esophagitis had a significantly higher percentage of 
CD25
+ 
CD4 cells before disease development compared to healthy individuals. Patients with 
advanced HIV without Candida esophagitis showed a two-fold lower percentage compared to 
patients with Candida esophagitis. We cannot state if these cells were activated or regulatory T 
cells, as we did not include additional markers. However, previous studies showed that a higher 
percentage of regulatory T cells was associated with lower HIV- and Candida-specific 
responses [27]. Furthermore, in vitro depletion of the Treg-containing CD25
+
 T-cell population 
greatly enhanced the response to HIV and CMV antigens [28-30]. Moreover, PD-1
+ 
CD4 cells 
significantly increased at diagnosis of Candida esophagitis, which further supports the 
assumption that a dysfunction of CD4 cells might be one factor leading to susceptibility to 
Candida esophagitis. 
Healthy individuals also show proliferation of CD8 cells in response to C. albicans. Previous 
work in mouse models has shown that in the absence of CD4 cells, CD8 cells were able to 
confer protection to the fungal pathogens Blastomyces dermatitidis and Histoplasma 
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capsulatum [31]. Interestingly, in our study we did not observe compensatory proliferation of 
CD8 cells in patients with low CD4 cell responses after stimulation with C. albicans. It is 
possible, that the CD8 cells proliferating to C. albicans in healthy individuals are mucosal-
associated invariant T (MAIT) cells that respond to C. albicans and are depleted in the course of 
HIV infection [32-34]. 
Recently, it has been shown that not only Th17 cells, but also other cells such as ILCs can be a 
source of IL-17 and are involved in the host defense against fungal infections [12]. We found 
that the ILC counts in peripheral blood of Candida esophagitis patients were unable to recover 
even with suppressed viral replication. Remarkably, patients with CD4 counts >350 cells/µl had 
significantly higher ILC counts in the peripheral blood compared to patients with CD4 counts 
<200 cells/µl, suggesting that the loss of ILCs occurs in parallel with the loss of CD4 counts 
over time and may additionally increase the risk of developing Candida esophagitis. 
Furthermore, recovery of ILCs after suppressed viral replication seems to be correlated with 
CD4 recovery. Nevertheless, these data should be interpreted with caution, as the number of 
patients is low and we did not investigate the different subsets of ILCs and their involvement in 
the mucosa.  
 
Also NK cells are increasingly considered as part of the host defense against fungi [13, 14, 35-
37]. Impaired NK-cell activity was observed in patients with chronic mucocutaneous 
candidiasis [38]. Also HIV-infected individuals show quantitative und functional NK-cell 
impairments that continue during disease progression, such as a decrease of the CD3
-
CD56
+
 cell 
subset, a decreased cytotoxic capacity and aberrant expression of several surface receptors [39-
42]. In fact, we found significantly lower NK-cell counts and a significantly lower percentage of 
CD16
+
 cytotoxic NK cells in patients with Candida esophagitis compared to healthy individuals 
and patients with early initiated cART. They did not recover under stable, virologically 
successful cART. Furthermore, similar to ILCs, NK-cell recovery seemed to correlate with CD4 
recovery.  
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Recently, evidence has accumulated that early initiation of cART is beneficial for virological as 
well as immunological parameters. Early treatment decreases cell-associated HIV RNA and 
DNA and limits the HIV reservoir [43-47], maintains numbers and function of the CD4 
compartment [4, 48-50] and reduces the risk for disease transmission and the development of 
opportunistic viral and fungal infections and malignancies [4, 51, 52]. However, it was not 
clear, how early or late treatment affects T-cell responses to opportunistic pathogens and how 
other immune cell subsets such as NK cells or ILC are affected. In this study we could confirm 
improved overall and Candida-specific CD4 recovery in patients with early cART. We could 
further show that ILC and NK-cell reconstitution, immune cells with a likely role in antifungal 
defense, correlated with CD4 recovery and was therefore superior in HIV-1-infected patients 
with early treatment, further arguing for early initiation of cART in HIV-1-infected individuals. 
 
The strength of this study is the comprehensive longitudinal analysis of quantitative and 
qualitative immune responses in a large number of HIV-infected patients with Candida 
esophagitis. This allowed identifying significant immunological impairments compared to 
healthy individuals and HIV-infected patients with early initiation of cART. However, due to 
the limited availability of PBMC we did not further characterize different cell subsets such as 
Treg or TH17 cells and functional analysis could not be performed in every sample. 
 
In conclusion, this study demonstrates that HIV-1-infected patients with Candida esophagitis 
not only have deficient T-cell responses, but an accumulation of multiple, partly Candida-
specific immunological defects. This may explain the fact that despite the high frequency of 
Candida esophagitis only a part of AIDS patients develop this OI. These defects are only 
partially reversible under cART and long-term immune impairments remain. This is particularly 
apparent in patients with low CD4 cell counts at initiation of cART showing greater general and 
Candida-specific immune impairments initially and under stable cART. Nevertheless, certain 
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individuals even experienced Candida esophagitis at higher CD4 counts. These patients showed 
similar immune defects as patients with low CD4 counts highlighting that the presence of 
specific immunological gaps is relevant. We hypothesize that specific gaps due to underlying 
genetic and/or immunological predisposition may explain why certain individuals also develop 
OI at higher CD4 counts. In line with other current studies, our study similarly supports the 
rationale for early initiation of cART.   
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Figures 
 
Fig. 1. Patients with Candida esophagitis have low and dysfunctional CD4 counts with 
decreased Candida-specific cytokine responses and proliferative capacity. (a) Absolute 
CD4
+
 T-cell counts, (b) percentage of PD1
+
 and CD25
+
 CD4
+
 T cells, (c) IFN-γ response of 
PBMC to SEB or heat-inactivated C. albicans, (d) IL-17 response of PBMC to SEB or heat-
inactivated C. albicans, (e) percentage of proliferating (CFSE
dim
) cells in the CD4
+
 T-cell 
population after 7 days stimulation with SEB or heat-inactivated C. albicans and (f) percentage 
of proliferating (CFSE
dim
) cells in the CD8
+
 T-cell population after 7 days stimulation with SEB 
or heat-inactivated C. albicans of patients at diagnosis of Candida esophagitis (ESO), patients 
with early initiated cART and a viral load (VL) <50 c/ml (VL<50) and healthy donors (HD). 
Shown are median values + interquartile ranges (Tukey plot). Data (c)-(f) are shown after 
subtraction of unstimulated controls. Number of ESO/VL<50/HD were n=37/15/20 (a), 
n=33/15/20 (b), n=18/11/19 (c), n=12/14/20 (d) and n=4/8/14 (e,f). * P≤.05, ** P≤.01, **** 
P≤.0001 (Mann-Whitney test). 
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Fig. 2. Patients with Candida esophagitis have decreased peripheral NK cells and innate 
lymphoid cells (ILC). (a) Absolute CD3
-
CD56
+ 
NK-cell counts, percentage of CD16
+
 NK cells 
and absolute CD16
+
CD3
-
CD56
+ 
NK-cell counts, (b) percentages of NKG2A
+
 and NKG2C
+
 NK 
cells, (c) percentage of proliferating (CFSE
dim
) cells in the NK-cell population after 7 days 
stimulation with SEB or heat-inactivated C. albicans and (d) absolute lineage
-
CD127
+ 
ILC-
count of patients at diagnosis of Candida esophagitis (ESO), patients with early initiated cART 
and a viral load (VL) <50 c/ml (VL<50) and healthy donors (HD). Shown are median values + 
interquartile ranges (Tukey plot). Data in (b) are shown after subtraction of unstimulated 
controls. Number of ESO/VL<50/HD were n=31/15/20 (a,b,d) and n=4/8/14 (c). ** P≤.01, *** 
P≤.001 **** P≤.0001 (Mann-Whitney test). 
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Fig. 3. Proliferative response to C. albicans and NK-cell counts and function are impaired 
despite higher CD4 counts at diagnosis. (a) Percentage of PD1
+
 and CD25
+
 CD4
+
 T cells, (b) 
IFN-γ response of PBMC to SEB or heat-inactivated C. albicans, (c) IL-17 response of PBMC 
to SEB or heat-inactivated C. albicans, (d) percentage of proliferating (CFSE
dim
) cells in the 
CD4
+
 T-cell population after 7 days stimulation with SEB or heat-inactivated C. albicans, (e) 
absolute CD3
-
CD56
+ 
NK-cell count, percentage of CD16
+
 NK cells, absolute CD16
+
CD3
-
CD56
+ 
NK-cell counts, percentages of NKG2A
+
 and NKG2C
+
 NK cells and (f) absolute lineage
-
CD127
+ 
ILC-count in patients with Candida ESO and CD4
+
 T-cell counts <200 cells/µl or >350 
cells/µl. Shown are median values + interquartile ranges (Tukey plot). Broken and dotted lines 
represent medians of healthy individuals (HD) and HIV-1-infected patients with early initiated 
cART and a viral load (VL) <50 c/ml (VL<50), respectively. Data (b)-(d) are shown after 
subtraction of unstimulated controls. Number of patients <200 / >350 CD4 were n=10/16 (a), 
n=8/7 (b), n=5/5 (c), n=1/3 (d), n=9/13 (e) and n=11/13 (f). * P≤.05, ** P≤.01 (Mann-Whitney 
test). 
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Fig. 4. Patients with Candida esophagitis retain immunological impairments after disease 
resolution and successful cART. Immune cell numbers and function of patients with Candida 
esophagitis 6-18 months before diagnosis (T-1), at the time of diagnosis (ESO), 6-18 months 
after disease resolution (T1) and after suppression of HIV-1 RNA for at least 2 years (T2). (a) 
Absolute CD4
+
 T-cell counts, (b) percentage of PD1
+
 and CD25
+
 CD4
+
 T cells, (c) IFN-γ 
response of PBMC to SEB or heat-inactivated C. albicans, (d) IL-17 response of PBMC to SEB 
or heat-inactivated C. albicans, (e) percentage of proliferating (CFSE
dim
) cells in the CD4
+
 T-
cell population after 7 days stimulation with SEB or heat-inactivated C. albicans, (f) percentage 
of proliferating (CFSE
dim
) cells in the CD8
+
 T-cell population after 7 days stimulation with SEB 
or heat-inactivated C. albicans, (g) absolute CD3
-
CD56
+ 
NK-cell counts, percentage of CD16
+
 
NK cells, absolute CD16
+
CD3
-
CD56
+ 
NK-cell counts, (h) percentages of NKG2A
+
 and 
NKG2C
+
 NK cells, (i) percentage of proliferating (CFSE
dim
) cells in the NK-cell population 
after 7 days stimulation with SEB or heat-inactivated C. albicans and (j) absolute lineage
-
CD127
+ 
ILC-count. Shown are median values + interquartile ranges. Broken and dotted lines 
represent medians of healthy individuals (HD) and HIV-1-infected patients with early initiated 
cART and a viral load (VL) <50 c/ml (VL<50), respectively. Data (c)-(f) and (i) are shown after 
subtraction of unstimulated controls. Number of patients T-1/ESO/T1/T2 were n=12/37/37/8 
(a), n=10/33/34/8 (b), n=3/18/27/6 (c), n=1/12/22/6 (d), n=3/4/6/6 (e,f), n=10/31/34/8 (g,h), 
n=3/4/6/5 (i) and n=10/31/36/8 (j). 
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Table 1.  Baseline characteristics. 
 
 Time point T-1 
6-18 months before  
diagnosis 
Time point T0 
Diagnosis of Candida esophagitis 
Time point T1 
6-18 months after    
diagnosis 
Time point T2 
After suppressed HIV      
RNA for > 2 years 
  
 ESO 
(n=12) 
 
No OI 
(n=8) 
 
 
<200 CD4 
(n=12) 
ESO 
(n=37) 
200-350 CD4 
(n=7) 
 
 
>350 CD4 
(n=18) 
 
 
<200 CD4 
(n=12) 
No OI                                                        
(n=37) 
200-350 CD4 
(n=7) 
 
 
>350 CD4 
(n=18) 
ESO
(n=37) 
No OI    
(n=37) 
ESO 
(n=8) 
No OI 
(n=8) 
Healthy 
(n=20) 
HIV patients 
with early 
cART  
(n=15) 
Median age  
(IQR) 
42 
(36-55) 
43 
(36-54) 
 
 
49 
(41-55) 
45 
(38-54) 
37 
(33-40) 
 
 
45 
(39-55) 
 
 
48 
(40-54) 
44 
(38-53) 
38 
(31-41) 
 
 
43 
(37-56) 
46 
(39-55) 
45 
(39-54) 
47 
(41-57) 
47 
(41-58) 
39 
(36-50) 
47 
(36-52) 
Sex, male  
(%) 
6 
(50) 
5 
(62.5) 
 
 
8 
(66.7) 
22 
(59.5) 
4 
(57.1) 
 
 
10 
(55.6) 
 
 
8 
(66.7) 
22 
(59.5) 
4 
(57.1) 
 
 
10 
(55.6) 
22 
(59.5) 
22 
(59.5) 
3 
(37.5) 
3 
(37.5) 
10 
(50) 
14 
(93.3) 
Median CD4
+
  
cells/ul (IQR) 
540 
(382-692) 
374 
(212-627) 
 
 
104 
(77-136) 
326 
(136-489) 
260 
(224-320) 
 
 
503 
(414-678) 
 
 
95 
(58-140) 
321 
(146-471) 
265 
(226-305) 
 
 
472 
(401-668) 
463 
(360-563) 
418 
(259-494) 
624 
(400-764) 
428 
(233-601) 
1225     
(1088-1378) 
785 
(701-1067) 
Median CD8
+
 
cells/ul (IQR) 
1032 
(795-1271) 
1217 
(972-1343) 
 
 
895 
(457-1536) 
922 
(630-1533) 
463 
(439-922) 
 
 
1063 
(837-1588) 
 
 
420 
(327-749) 
781 
(457-1265) 
671 
(561-1191) 
 
 
1173 
(842-1768) 
1004 
(660-1580) 
870 
(613-1280) 
936 
(607-1254) 
882 
(519-957) 
555            
(463-638) 
680 
(610-1290) 
Median 
lymphocytes 
2261 
(1584-2522) 
2164 
(1736-2888) 
 
 
1863 
(1232-2420) 
 
 
 
 
1457 
(1146-2000) 
 
 
2013 
(1528-2773) 
1765 
(1323-2274) 
2268 
(1446-2999) 
1881 
(1229-2383) 
- 2002 
(1588-3030) 
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cells/ul (IQR) 1232 
(728-2000) 
1446 
(1060-1848) 
2056 
(1782-2922) 
876 
(640-1201) 
1307 
(1148-1890) 
2365 
(1690-2881) 
 
HIV RNA 
log10 
copies/ml 
(IQR) 
2.3 
(1.2-4.3) 
3.1 
(1.2-4.5) 
 
 
5.3 
(3.2-5.6) 
3.6 
(2.7-5.6) 
5.1 
(3.3-6.9) 
 
 
3.0 
(2.2-3.7) 
 
 
3.9 
(2.6-5.2) 
4.0 
(2.7-4.4) 
4.5 
(4.0-4.8) 
 
 
3.6 
(2.3-4.3) 
2.5 
(1.6-4.3) 
3.4 
(2.3-4.2) 
<50 
copies/ml 
<50 
copies/ml 
- <50 
copies/ml 
cART  
(%) 
11 
(91.7) 
7 
(87.5) 
 
 
6 
(50) 
26 
(70.3) 
6 
(85.7) 
 
 
14 
(77.8) 
 
 
8 
(66.7) 
23 
(62.2) 
5 
(71.4) 
 
 
10 
(55.6) 
36 
(97.3) 
31 
(83.8) 
8 
(100) 
8 
(100) 
- 15 
(100) 
CMV-
positive  
(%) 
11 
(91.7) 
7 
(87.5) 
 
 
11 
(91.7) 
31 
(83.8) 
4 
(57.1) 
 
 
16 
(88.9) 
 
 
9 
(75) 
31 
(83.8) 
5 
(71.4) 
 
 
17 
(94.4) 
31 
(83.8) 
31 
(83.8) 
6 
(75) 
2 
(25) 
- 13 
(86.7) 
HCV-
positive  
(%) 
5 
(41.7) 
2 
(25) 
 
 
4 
(33.3) 
10 
(27) 
1 
(14.3) 
 
 
5 
(27.8) 
 
 
3 
(25) 
8 
(21.6) 
1 
(14.3) 
 
 
4 
(22.2) 
10 
(27) 
8 
(21.6) 
4 
(50) 
2 
(25%) 
- 1 
(6.7) 
Sample 
dates (year-
year) 
2001-2010 2001-2007  2001-2011 
 
 
  2000-2012  2002-2012 2001-2013 2008-2014 2008-2014 2014 2014 
 
 
ESO, patients with Candida esophagitis; No OI, patients with advanced HIV infection without opportunistic infection; cART, combined antiretroviral therapy; IQR, interquartile range; CMV, 
cytomegalovirus serology; HCV, hepatitis C serology. 
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